Please try another search
For the fiscal year ended 31 March 2021, BioferminPharmaceutical Co Ltd revenues decreased 9% to Y10.81B. Netincome applicable to common stockholders decreased 31% toY1.55B. Revenues reflect New BioferminS segment decrease of14% to Y6.48B, BioferminR segment decrease of 33% toY380.5M. Net income also reflects Sales promotion expensesincrease of 23% to Y479.3M (expense), Reserve for salespromotion increase of 50% to Y107.6M (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 2691.68 | 2753.16 | 2410.58 | 2955.76 |
Gross Profit | 1316.59 | 1636.59 | 1531.16 | 1829.61 |
Operating Income | -82.57 | 678.09 | 531.71 | 912.97 |
Net Income | -34.98 | 515.89 | 383.7 | 683.77 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 33384.94 | 32817.22 | 32926.68 | 32972.08 |
Total Liabilities | 2943.43 | 2445.26 | 2707.44 | 3119.63 |
Total Equity | 30441.51 | 30371.97 | 30219.24 | 29852.46 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | 1922 | 1124.33 | ||
Cash From Investing Activities | -4591.4 | -1321.35 | ||
Cash From Financing Activities | -717.79 | -359.35 | ||
Net Change in Cash | -3387.18 | -556.37 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review